Sign up
Log in
Why Is Gain Therapeutics (GANX) Stock Down 25% Today?
Share
Listen to the news

This public offering has Gain Therapeutics selling 7,116,547 shares and pre-funded warrants for 1,031,602 shares. The shares are being sold for $1.35 each with the warrants having the same price minus $0.0001.

The pre-funded warrants in this offering are exercisable immediately after being issued. They have an exercise price of $0.0001.

Gain Therapeutics is also offering underwriters the option of acquiring another 1,222,222 shares in this public offering. Titan Partners Group is acting as the sole bookrunner for this offering.

Gain Therapeutics expects to raise $11 million in gross proceeds from this public offering. It will use these funds to continue the clinical and nonclinical development of GT-02287. This is its lead product candidate to treat neurodegenerative diseases. The money may also be used for general corporate purposes.

How This Affects GANX Stock

With this public offering, Gain Therapeutics is increasing the total number of outstanding shares. Doing so dilutes the stakes of current investors in the biotechnology company. That’s one reason why the stock is down today.

Another is the pricing of shares in the offering. The $1.35 price is well below the stock’s previous closing price of $1.89 per share. It makes sense this discount would drop the price of currently traded shares too.

GANX stock is down 25.4% as of Friday morning.

Investors will want to stick around for more of the most recent stock market news!

We have all of the hottest stock market stories ready to go on Friday! That includes everything happening with shares of Nexalin Technology  (NASDAQ:NXL) stock, Chijet Motor  (NASDAQ:CJET) stock and Foxo Technologies  (NYSEMKT:FOXO) stock today. All of this news is available at the following links!

More Stock Market News for Friday

On Penny Stocks and Low-Volume Stocks: €¯With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That's because these "penny stocks" are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that €¯InvestorPlace.com's writers disclose this fact and warn readers of the risks.

Read More: €¯Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

More From InvestorPlace

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.